Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

0 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

About Bayer Schering Pharma

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com .

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at http://www.baye
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...., Sept. 5 /PRNewswire-USNewswire/ -- A team of,re...at U.S. immigrants from,India and Pakistan take on...heir risks of prostate cancer among male immigrant...r and prostate cancer develop due to many reasons,...jor role in these cancers,",said Jame Abraham, M.D...
(Date:9/4/2008)... in TaqMan(R) real-time PCR testing for the diagno...NTON, Calif., Sept. 4 /- The U.S. Foo...he COBAS(R) TaqMan(R) HBV Test,the first assay fo...he U.S.,The test uses Roche,s real-time PCR techno...NA in a patient,s blood. Doctors may use viral loa...
(Date:9/4/2008)...and, September 4 /- Axentis Pharma AG...s the safety and tolerability,of a new therapeutic...,infection in cystic fibrosis patients. The new fo...to be delivered directly to the site of,infection....ts of two,different doses of the new drug. Initial...
(Date:9/3/2008)...a, Sept. 4 /Xinhua--,Pharma...) today announced,that it has enrolled the first s...ial evaluating Bronchitol in cystic fibrosis suffe... hospitals across North,America, Argentina and Ger...xis seeks approval to market Bronchitol for cystic...
Breaking Medicine Technology:Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 2Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 3Body Image is a Concern for Students of All Ages 23875 1Body Image is a Concern for Students of All Ages 23875 2Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 1Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 2Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 1Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 2Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 1Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 2
... II GBM study presented at ASCO with cediranib - a... quarter of patients alive,and progression- free a...e/ -- Data for the,investigational agent cediranib...ing of the American Society of Clinical Oncology,(...blastoma (GBM),an invasive form of brain tumor wi...
...itive data on subcutaneous administration show pot...atients -, CHICAGO, June 04, 2007 /PRNewswire-Firs...nnounced the presentation of positive,data for VEL...,multiple myeloma (MM) who have received at least ... a Phase II trial for subcutaneous,(SC) administra...
Other Medicine Technology:Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 7
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...responsible for checking the profits and safety of... to the NHS. They have to monitor that only brande...ould be reasonable. The Pharmaceutical Price Regu...nization which monitors and legislates the agreeme...
...ve come up with a disaster-planning guide to help ...nted by tropical storms, hurricanes, tidal waves a...world, people are vulnerable to some sort of natur...ke, flood, hurricane, or tornado. In addition, ter...
...ed over the increasing malfunction of heart device... deaths between 1990 and 2002. The Food and Drug A...ng with physicians and heart-device manufacturers ...llators had failed between 2000 and 2003. Same num...
...he damages in the heart from the use of stem cells...s from mice to repair heart damage in sheep, repor...sue of The Lancet. Heart failure is a major cause ...es, occurring when cells within the heart are dama...
Other Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device.
Clinicians are demanding smaller, higher performing systems specifically designed to meet their clinical and operational challenges. The new Philips HD11 XE system provides a powerful architecture fo
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea
InfinixTM CF-i/SP brings revolutionary flexibility to floor-mounted X-ray systems. The unique design enables operators to move the C-arm around the exam table as needed to obtain the optimal angle fo
Medicine Products: